The FDA approved Pfizer and Astellas Pharma's Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration-resistant prostate cancer. The drug was previously approved to treat metastatic castration-resistant prostate cancer.
Pfizer, Astellas' Xtandi OK'd for second prostate cancer variant
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.